(fifthQuint)The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF).

 INSPIRE, the largest and most comprehensive clinical trial ever conducted in IPF, has now completed enrolling patients with mild to moderate IPF.

 Eligible patients will receive either Interferon gamma-1b or placebo for a minimum of 2 years.

.

 The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)@highlight

- Purpose: A phase 3, randomized, double-blind, placebo-controlled trial to determine the efficacy and safety of 200 mu g of recombinant Interferon gamma-1b administered by subcutaneous (SC) injection, compared with placebo, in patients with IPF - Enrollment: Approximately 800 patients will be enrolled from approximately 80 centers in North America and Europe - Randomization: 2:1 active-to-placebo ratio - Duration: at least 2 years active drug or placebo (rescue therapy will be permitted for patients who meet predefined criteria)